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Abstract
Background: Brimonidine is a common drug for lowering ocular pressure and may directly protect retinal
ganglion cells in glaucoma. The disease involves early loss of retinal ganglion cell transport to brain targets
followed by axonal and somatic degeneration. We examined whether brimonidine preserves ganglion cell axonal
transport and abates degeneration in rats with elevated ocular pressure induced by laser cauterization of the
episcleral veins.
Results: Ocular pressure was elevated unilaterally by 90% for a period of 8 weeks post- cauterization. During this
time, brimonidine (1mg/kg/day) or vehicle (phosphate-buffered saline) was delivered systemically and continuously
via subcutaneous pump. Animals received bilateral intravitreal injections of fluorescent cholera toxin subunit b
(CTB) two days before sacrifice to assess anterograde transport. In retinas from the vehicle group, elevated pressure
induced a 44% decrease in the fraction of ganglion cells with intact uptake of CTB and a 14-42% reduction in the
number of immuno-labelled ganglion cell bodies, with the worst loss occurring nasally. Elevated pressure also
caused a 33% loss of ganglion cell axons in vehicle optic nerves and a 70% decrease in CTB transport to the
superior colliculus. Each of these components of ganglion cell degeneration was either prevented or significantly
reduced in the brimonidine treatment group.
Conclusions: Continuous and systemic treatment with brimonidine by subcutaneous injection significantly
improved retinal ganglion cell survival with exposure to elevated ocular pressure. This effect was most striking in
the nasal region of the retina. Brimonidine treatment also preserved ganglion cell axon morphology, sampling
density and total number in the optic nerve with elevated pressure. Consistent with improved outcome in the
optic projection, brimonidine also significantly reduced the deficits in axonal transport to the superior colliculus
associated with elevated ocular pressure. As transport deficits to and from retinal ganglion cell projection targets in
the brain are relevant to the progression of glaucoma, the ability of brimonidine to preserve optic nerve axons and
active transport suggests its neuroprotective effects are relevant not only at the cell body, but throughout the
entire optic projection.
Background
Glaucoma is a chronic disease that causes vision loss
through the degeneration of retinal ganglion cell (RGC)
neurons and their axons in the optic nerve [1,2]. While
age is an important risk factor, the only modifiable risk
factor and sole target for clinical intervention is elevated
intraocular pressure (IOP) or ocular hypertension (OHT)
[3]. Lowering IOP generally slows progression in glau-
coma [3], but does not necessarily stop degeneration [4].
Thus, there is great interest in identifying neuroprotec-
tive agents as potential therapies [5,6].
Brimonidine (BMD; UK14304, Alphagan) is a non-
selective a2-adrenergic receptor agonist currently used
as a treatment to lower IOP in glaucoma. An effect of
BMD is to decrease aqueous humor production by inhi-
bition of adenylate cyclase inhibition, which lowers
cAMP levels [7]. The drug also increases uveoscleral out-
flow due to prostaglandin release and/or ciliary muscle
relaxation [8]. Independent of its IOP-lowering proper-
ties, BMD is neuroprotective for RGCs in various injury
models [9-13]. Potential mechanisms underlying these
effects include the inhibition of glutamate release,
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any medium, provided the original work is properly cited.regulation of calcium influx in the inner retina, modula-
tion of NMDA receptor signalling in RGCs, and upregu-
lation of trophic factor expression [14-16]. Because of its
dual action to lower IOP and perhaps protect against
neuronal injury, BMD may hold promise in the treatment
of glaucoma and other optic neuropathies [17].
F o l l o w i n ga c u t ei s c h e m i ci n j u r y ,B M Dp r e s e r v e sa x o -
nal transport along RGC axons from the retina to the
superior colliculus [18]. This is intriguing in the context
of glaucoma, as recent evidence indicates axon-specific
mechanisms play an early role in the pathology of the
disease [19-21]. Here we investigated whether systemic
treatment with BMD by continuous subcutaneous injec-
tion improves axon survival in the optic nerve and ante-
rograde transport to the colliculus with acute OHT.
Results
Systemic brimonidine treatment does not affect IOP
We induced OHT unilaterally in rats using laser photo-
coagulation of episcleral and limbal veins as described
below. Systemic treatment with either BMD (1 mg/kg/day)
or vehicle (phosphate-buffered saline, PBS) began at the
time of initial IOP elevation and continued for the 8 week
period of elevation. We chose this dosing regimen based
on previous experiments examining the effects of systemic
BMD on RGC survival with elevated ocular pressure [11].
Eyes without laser injury (naïve, vehicle control, BMD
control) had an average IOP of 15.5 ± 0.1 mmHg that did
not differ between groups (p = 0.59; Figure 1). One week
following induction of OHT, IOP reached a peak of 32.3 ±
0.1 mmHg in both vehicle and BMD OHT eyes (p = 0.96).
Thereafter IOP remained elevated by 90 ± 6% in the
vehicle group and by 91 ± 7% in the BMD group com-
pared to the control eye (p = 0.85); neither changed signif-
icantly over the experimental period (p ≥ 0.2). Thus,
systemic delivery of BMD by subcutaneous osmotic pump
had no effect on IOP (Figure 1).
Brimonidine prevents loss of RGCs with OHT
We compared the localization of CTB and phosphorylated
heavy-chain neurofilaments (SMI31) in whole-mounted
retinas from naïve, vehicle and BMD rats (Figure 2). In
naïve, vehicle and BMD control retinas, nearly every RGC
labelled by SMI31 also demonstrated intact CTB uptake
(Figure 2A-D,G). Vehicle OHT retinas contained far fewer
CTB+ and SMI31 + RGCs (Figure 2E,F). In these retinas,
RGC axons also contained less CTB, indicative of dimin-
ished active uptake and transport, and more intense con-
centration of SMI31, suggesting accumulation. Vehicle
OHT retinas also showed obvious axonal dystrophy,
swelling of RGC somas, and accumulation of SMI31 in
RGC dendrites. In contrast, OHT retinas from BMD trea-
ted rats appeared similar to naïve and control retinas with
respect to SMI31 and CTB localization (Figure 2H,I). Few,
if any, dystrophic axons or swollen RGCs were observed in
these retinas.
Next we quantified the number of SMI31+ and CTB+
RGCs in each group. For simplicity, we represent the
R G Cc o u n t sa st h er a t i oo ft h er i g h tt ol e f tr e t i n af o r
the naïve group and as the ratio of OHT to control
retina for the vehicle and BMD groups (Figure 3). As
expected, for the naïve group the ratios for both SMI31
and CTB counts were identical to one, indicating no dif-
ference between the right and left eyes (p ≥ 0.22). In the
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Figure 1 Systemic BMD does not affect IOP. Ocular pressure in mmHg as measured using TonoLab following laser photocoagulation of
episcleral veins at two time points (arrows). Systemic BMD (1 mg/kg/day) delivered via subcutaneous osmotic pump did not affect IOP for
control or OHT eyes compared to vehicle treatment (p ≥ 0.6; mean ± SEM; n = 16 eyes per group).
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Figure 2 BMD preserves RGC morphology in retinas exposed to OHT. (A-C) Representative confocal images of whole-mounted naïve rat
retina demonstrating co-localization of CTB (green) with phosphorylated heavy-chain neurofilament (SMI31; red) in RGC axons (dashed lines) and
somas (open arrowheads). Similar co-localization was observed in vehicle (D) and BMD (J) control retinas. Vehicle OHT retinas (E-I) demonstrated
fewer CTB + RGC somas and axons, dystrophic axons (arrowheads), and swollen RGCs with dendrites accumulating SMI31 (arrows). In BMD OHT
retinas (K, L), co-localization of CTB and SMI31 was similar to that in naïve and control retinas. Distance from optic disc is 1 mm (A, D, E, G, J, K),
2 mm (B, H, I), or 4 mm (C, F, L).
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Page 3 of 13vehicle group, the number of CTB + RGCs in the OHT
retina was only 56% that of the control retina, which
was a significant reduction (p = 0.01). BMD completely
prevented this decrease: the ratio of the OHT to control
eye was the same as the naïve group (p = 0.42). Com-
pared to the vehicle group, this was a dramatic improve-
ment of 200% (p < 0.001). In terms of SMI31+ RGCs, in
the vehicle group, the number in the OHT retina was
84% that of the control retina, which was not significant
(p = 0.26). In the BMD group, the number of SMI31+
RGCs was the same for both eyes and not distinguish-
able from naïve (p = 0.11).
Figure 3 indicates a large variability for the vehicle
group in terms of the effects of OHT on RGC number,
with standard errors 25 - 30% of the mean for both
CTB+ and SMI31+ cells. To determine if the variability
was retinotopic, as in other models [22-25], we quanti-
fied SMI31+ RGCs along the midline of each retinal
quadrant as a function of eccentricity from the optic
disc (Figure 4). In naïve retinas RGC density ranged
from 2,900 to 5,400 RGCs/mm
2 with a mean across
quadrants of 4000 ± 170 RGCs/mm
2.T h i si sc o m p a r -
able to published values for RGC density for this species
[25,26]. The number of labelled RGCs in vehicle control
retinas was slightly higher for the inferior and nasal
quadrants (4600 ± 440 RGCs/mm
2), but this difference
was not significant compared to naïve (p ≥ 0.1). Across
quadrants, we found no difference in RGC density
between vehicle control (4200 ± 330 RGCs/mm
2)a n d
BMD control (4025 ± 174 RGCs/mm
2) retinas (p ≥ 0.2),
so these were combined in the comparisons that follow
(Figure 4).
For all retinal quadrants, the density of SMI31+ RGCs
in the control retinas peaked within 1-2 mm of the
optic nerve head (3,400 to 5,400 RGCs/mm
2)a n d
decreased slightly (17 to 18%) at 4 mm out (Figure 4).
In the superior retina of the vehicle group, OHT
decreased RGC density by 15 to 17% across eccentricity
compared to control eyes. RGC density in the same sec-
tor for the BMD OHT retinas was 14 - 24% higher than
the vehicle OHT retinas; neither group was significant
different than the corresponding control eye (p ≥ 0.2).
In the inferior quadrant of vehicle retinas, OHT
decreased RGC density 14 - 25% compared to control
retinas with significant reductions of 25% and 23%
observed at 1 and 2mm eccentric, respectively (p ≤
0.05). For the BMD group in this quadrant, RGC density
did not change with OHT compared to control (p ≥
0.25). In the temporal quadrant for vehicle retinas, OHT
decreased RGC density 14 - 27% compared to control;
at 4mm eccentricity this decrease (27%) was significant
(p = 0.04). For the BMD group in this quadrant, RGC
density in OHT retinas was similar to control retinas at
all eccentricities (p ≥ 0.2). The 31% improvement in
RGC density compared to vehicle OHT retinas was sig-
nificant at 1 mm from the optic disc (p = 0.05). Finally,
RGC loss in vehicle OHT eyes was most dramatic in the
nasal retina, where RGC density decreased at every loca-
tion. Decreased density compared to control retinas ran-
ged from 42% nearest the optic disc to 26% at 4 mm
eccentricity (p ≤ 0.02). BMD treatment afforded partial
rescue of RGCs in this quadrant, with significant
increases of 30-42% at 1-3 mm eccentricity compared
to vehicle OHT retinas (p ≤ 0.005). However, only at
1 mm was RGC density in the BMD OHT group com-
parable to the control group (p = 0.09).
Brimonidine protects RGC axons
We compared RGC axon morphology and survival
after OHT in cross sections of vehicle- and BMD-trea-
ted optic nerves. Vehicle OHT nerves (Figure 5A and
5B) displayed degenerating axon profiles and gliotic
scarring compared to vehicle control nerves (Figure
5C). In contrast, BMD OHT nerves were similar in
appearance to control nerves, with few if any degener-
ating profiles (Figure 5D). We quantified axon density
(axons/mm
2) and total number of axons for each
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Figure 3 BMD preserves CTB uptake by RGCs during OHT.B a r
chart shows CTB+ and SMI31+ RGCs as the ratio of OHT to control
retina for the vehicle- and BMD-treated rats (mean ± SEM; n = 6
retina each). The naïve group is represented simply as the ratio of
the right to left retina. In the vehicle group, OHT decreased the
number of CTB+ RGCs so that the ratio was significantly less than
one (*, p = 0.01). Treatment with BMD improved CTB uptake in OHT
retinas compared to vehicle (**, p < 0.001). The number of SMI31+
RGCs in vehicle-treated retinas was also decreased by OHT, but this
result was not significant. The ratio of OHT to control eye for both
CTB+ and SMI31+ RGCs was identical for the naïve and BMD-
treated rats (p ≥ 0.11).
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Page 4 of 13group. Once again for simplicity, these are shown as
t h er a t i oo ft h er i g h tt ol e f tn e r v ef o rt h en a ï v eg r o u p
and as the ratio of the OHT to control nerve for the
vehicle and BMD treated groups (Figure 5E). As
expected, both ratios were identical to one for the
naïve, indicating no difference between the two eyes.
For the vehicle group, axon density was 25% less and
the number of axons 33% less in the OHT nerve com-
pared to control, yielding ratio that differed signifi-
cantly from one (p ≤ 0.03). Conversely, for BMD-
treated animals both axon density and axon number
were similar between the OHT and control nerves,
yielding ratios identical to those for naïve rats (p ≥
0.3). Both measures were considerably improved com-
pared to vehicle-treated rats (p = 0.011).
Brimonidine substantially restores anterograde transport
We compared anterograde transport of CTB from the
retina to the superior colliculus in naïve, vehicle-, and
BMD-treated animals (Figure 6). Complete CTB labelling
of the RGC-recipient zone was observed in colliculi from
naïve eyes (Figure 6A) and in colliculi from control eyes
in the vehicle group (Figure 6B). The corresponding reti-
notopic maps for these colliculi were reconstructed from
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Figure 4 BMD prevents modest RGC somatic loss with OHT. RGC density is shown for control, vehicle- and BMD-treated groups across
eccentricity (mean ± SEM; n = 6 retina each). RGC density decreased with OHT in vehicle retinas compared to control at all locations in each
quadrant, with significant decreases indicated (*). In BMD-treated rats, RGC density with OHT was the same as control retinas except at 3
locations in the nasal quadrant (†,p≤ 0.02) and was significantly higher than vehicle OHT retinas at locations in both temporal and nasal
quadrants (§, p ≤ 0.05). Inset: Diagram showing locations in retinal quadrants 1-4 mm eccentric from the optic disc (black circle) for which SMI31
+ RGCs were quantified. Size of each field is 0.101mm
2.
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Page 5 of 13serial sections. These showed complete representations of
CTB signal except for the retinal optic disc gap, which
contains no RGCs. Complete labelling of colliculi from
control eyes of the BMD-treated group was also observed
(data not shown). In contrast, colliculi from vehicle OHT
eyes demonstrated severe deficits in CTB signal, ranging
from a retinotopic hemifield (Figure 6C, left) to nearly
complete loss (Figure 6C, right). OHT in the BMD group
had far less affect on CTB transport to the colliculus,
yielding retinotopic representations ranging from com-
plete (Figure 6D, left) to mild deficits (Figure 6D, right).
When quantified as the fraction of intact retinotopic map
(Figure 6E), as expected CTB transport to the colliculus
was similar for the two eyes of the naïve group (p ≥ 0.18).
Similarly, there was no difference in intact transport
between naïve colliculi and colliculi from the control
eyes for both the vehicle and BMD groups (p ≥ 0.49).
With OHT for vehicle rats, the average deficit in CTB
transport was 71.8 ± 6.4%. With a range of intact trans-
port of only 2 - 58%, this represented a significant reduc-
tion compared to control eye transport (93.4 ± 3.0%
intact, p = 0.001). For the BMD group, OHT-induced
deficits were far less, with an average deficit of 36.9 ±
7.8% and a range of intact transport of 36 - 97%. While
this range was decreased compared to control eye colli-
culi for the group (97.0 ± 1.5% intact, p = 0.004), BMD
treatment improved transport by 124% compared to the
OHT colliculi for vehicle animals (p = 0.002).
We found earlier that the most dramatic reduction in
RGC density in the retina was in the nasal quadrant
(Figure 4). In other animal models of glaucoma, loss of
anterograde transport to the superior colliculus is also
spatially-specific, filling in one retinal sector completely
before affecting another [21]. We found that typically,
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Figure 5 BMD preserves RGC axon morphology, density and total number following OHT. High-magnification light photomicrographs
demonstrating degenerating axon profiles (arrowheads) and gliotic scars (asterisks) in cross-sections of vehicle OHT optic nerves (A and B). Like
vehicle control nerve (C), nerves from BMD OHT rats (D) had significantly fewer degenerating profiles. (E) Axon density and total axon number
expressed as the ratio of OHT to control nerve for vehicle and BMD groups; naïve group is the ratio of the right to left nerve (mean ± SD; n =
16 each). Density and axon number decreased in vehicle treated rats so that the ratio for each differed significantly from one (*, p ≤ 0.02). BMD
treatment improved both outcome measures compared to vehicle (**, p = 0.011).
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Figure 6 BMD partially preserves anterograde transport following acute IOP elevation. (A) Representative cross-section through medial
superficial superior colliculus (left, outlined) from naïve rat showing normal RGC anterograde transport of CTB (green). Corresponding retinotopic
map reconstructed from serial cross-sections through the colliculus (right) shows representation of optic disc gap (circle). Colorimetric scale
indicates levels of transport from 100% (red) to 50% (green) to 0% (blue). (B) Comparable colliculus section (left) and retinotopic map (right)
corresponding to vehicle control eye also shows intact transport. (C) Sections of colliculus corresponding to OHT eye in vehicle group show deficits
ranging from sectorial (arrowheads on left) to complete loss (right). Corresponding retinotopic maps were 58% (left) and 7% (right) intact,
respectively. (D) Colliculus from OHT eye in BMD-treated rats show range of rescued transport from complete (left) to modest (85% intact, right).
(E) CTB transport in colliculus calculated as the fraction of the retinotopic map with ≥70% maximum signal for three groups (mean ± SEM; n = 11
each). Naïve group represents transport to the left and right colliculi. OHT decreased CTB transport 70% in vehicle-treated rats (*, p = 0.001) but
only 35% in BMD-treated animals (*, p = 0.004). BMD significantly improved transport with OHT when compared to vehicle eyes (**, p = 0.002).
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Page 7 of 13transport deficits due to OHT in the vehicle group were
quite severe (see above), so spatial progression was diffi-
cult to assess. However, when we transformed the reti-
notopic maps of colliculus transport into retinal
quadrant and eccentricity coordinates following Siminoff
et al. [27] and Drager and Hubel [28], we found hints
that deficits due to OHT begin nasally. Compared to
naïve or control (Figure 7A), for vehicle colliculi, moder-
ate OHT-induced transport deficits (42% to 57% loss)
filled in from the nasal retina to the optic disk represen-
tation (Figure 7B). In vehicle colliculi with severely
affected transport (>80% loss), deficits continued to
spread from the nasal representation to the optic disc
and into other retinal sectors. Even the more modest
transport deficits from OHT eyes in the BMD-treated
group appeared to follow the same geographic progres-
sion (Figure 7D).
Discussion
In this study, we quantified how systemic delivery of
BMD via subcutaneous osmotic pump protected RGCs
challenged by elevated IOP in a rat model of OHT. In
the absence of treatment, OHT for 8 weeks induced
pathology at several levels. In the vehicle group, the
worst OHT-related outcome was 70% depletion in
transport of CTB to the superior colliculus (Figure 6).
This deficit cannot be accounted for entirely by loss of
active uptake of CTB by RGCs in the retina, which was
reduced by only 44% (Figure 3). Depletion of transport
was followed by a 33% loss of axons in the optic nerve
( F i g u r e5 )a n df i n a l l yb ya na v e r a g ed e c r e a s ei nR G C
somatic density of about 16% as measured by SMI31
labelling (Figure 4). In the retina, OHT was also asso-
ciated with severely dystrophic axons, swollen RGC
somas, and the accumulation of phosphorylated neurofi-
laments in dendrites (Figure 2).
These results support an OHT-induced progression in
which a functional deficit precedes structural pathology.
Loss of active uptake and transport of CTB was far worse
than axon loss in the optic nerve, which in turn was worse
than RGC somatic drop-out in the retina. This progression
is similar to that described in the DBA2J mouse model of
glaucoma [20,21,23]. Interestingly, RGC somatic loss as
measured by SMI31 labelling was not uniform. Rather, it
was worst in the nasal retina, where OHT decreased RGC
density 26 to 42% across eccentricities (Figure 4). This
spatial progression too is consistent with the sectorial pat-
tern of RGC pathology observed in other glaucoma mod-
els [22,23,29,30]. Though axonal transport to the superior
colliculus was severely affected by OHT, our retinotopic
maps also hint of sectorial progression (Figure 7; [21]).
Although there is some earlier evidence that BMD can
preserve optic nerve axons and RGC axonal transport
after acute injury [9,31,32], previous studies of BMD’s
effect in glaucoma models have focused on retinal out-
comes [11,12,16,33,34]. Following episcleral vein cautery,
BMD delivered via intraperitoneal injection prevented
OHT-induced loss of RGC cell bodies labelled by retro-
grade transport of FluoroGold from the colliculus [12,33].
In studies similar to ours in which OHT was induced by
laser photocoagulation of episcleral and limbal veins for
3 weeks, BMD delivered by subcutaneous pump also
improved the number of RGCs labeled retrogradely
[11,16,34]. Our results are in agreement with these pre-
vious studies in that systemic BMD delivery increased
RGC cell body survival (Figure 3 and Figure 4), even for
our much longer period of OHT. However, given recent
evidence that RGC somatic loss occurs late in disease pro-
gression [20], we examined axonal transport to the collicu-
lus and axon survival in the nerve, both of which are
challenged much earlier [21].
We found that systemic BMD treatment via subcuta-
neous delivery ameliorated the effects of OHT on each of
our outcome measures. In the retina, BMD preserved
RGC axonal and dendritic morphology (Figure 2),
restored CTB uptake (Figure 3), and increased the num-
ber of SMI31+ RGCs, especially in the nasal retina where
OHT-induced loss was greatest (Figure 4). In the optic
nerve, BMD restored the axonal population to control
levels as well (Figure 5). Finally, BMD improved antero-
grade axonal transport to the SC by 124% (Figure 6). As
transport deficits to and from RGC targets are relevant to
the progression of glaucoma [20,21], the ability of BMD
to preserve optic nerve axons and axonal transport sug-
gest its neuroprotective effects are pertinent not only at
RGC soma, but throughout the entire retinal projection.
BMD is a non-subtype-selective a2-adrenergic receptor
agonist. All three a2 receptors subtypes are expressed in
the retina, with expression of a2A and a2B receptors by
RGCs and a2B receptors by glia [35,36]. Activation of a2
receptors within the retina elicits many responses including
reduced glial activation [11,37], decreased oxidative stress
[38,39] and protection against apoptosis [40-42]. In addi-
tion, BMD may protect RGCs by regulating intracellular
Ca
2+ levels and glutamate availability within the retina
[16,43]. Excess glutamate can result in RGC apoptosis via
overstimulation of NMDA receptors and subsequent
increases in intracellular Ca
2+.S t i m u l a t i o no fa2r e c e p t o r s
also results in the activation of the phosphatidylinositol 3
kinase (PI3K) pathway [44,45]. Activation of the PI3K path-
way promotes RGC survival after various injuries [46,47],
perhaps by altering gene expression [48-50], regulating
protein activity [51,52], or by affecting cellular metabolism
[53,54]. These and other responses make a2 agonists like
BMD ideal neuroprotective agents within the retina.
A potential mechanism underling the neuroprotective
effect of BMD on RGC axons involves the inactivation of
glycogen synthase kinase-3 (GSK3) via the PI3K pathway.
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Figure 7 Deficits in anterograde transport begin in the nasal retina. Retinotopic maps of CTB transport transformed into retinal quadrant
and eccentricity coordinates following Siminoff et al. (1966) [27] and Drager and Hubel (1976) [28]. (A) Colliculus maps for naïve (left), vehicle-
group control (middle) and BMD-group control (right) eyes are complete (98-99%) and show location of optic disk (*). (B) Moderate transport
deficits (shaded regions) in colliculi from vehicle OHT eyes with 58%, 50% and 43% intact transport (left to right respectively) appear to spread
from the nasal retinal representation to the optic disk. (C) Moderate to severe transport deficits in vehicle OHT colliculi with 39%, 19% and 2%
intact transport (left to right respectively) continue to spread from the optic disk to other retinal quadrants. (D) BMD treatment ameliorates most
transport deficits (96% intact, left) but the same spatial pattern of progression applies for even modest deficits (84% and 80% intact, middle and
right respectively). Abbreviations: I, N, S, T indicate inferior, nasal, superior and temporal quadrants of the retina, respectively.
Lambert et al. Molecular Neurodegeneration 2011, 6:4
http://www.molecularneurodegeneration.com/content/6/1/4
Page 9 of 13GSK3 is a constitutively active and ubiquitous kinase. In
neurons, GSK3 phosphorylates microtubule-associated
protein 1B, resulting in loss of stable microtubules [55].
GSK3 also phosphorylates collapsin response mediator
protein-2, which promotes microtubule assembly and
links tubulin heterodimers to kinesin-1 to regulate pro-
tein transport to distal regions of axons [56-58]. Also,
GSK3 activation is implicated in hyper-phosphorylation
of axon cytoskeletal proteins, including neurofilaments
[59,60]. Interestingly, GSK3 can be inactivated by down-
stream kinases in the PI3K pathway [61-63], thus provid-
ing a possible link between a2 receptor activation and
preservation of the axonal cytoskeleton. Activation of the
PI3K pathway via treatment with BMD could counteract
these changes, consequently preserving both axonal
transport and structure. Since BMD applied either topi-
cally to the cornea or via systemic injection reaches the
posterior segment in appreciable concentrations [64], its
use could represent a viable intervention for combating
early axon deficits in glaucoma.
Conclusions
Ocular hypertension in rats resulted in a substantial
decline in RGC axonal transport to the superior collicu-
lus, diminished axon survival in the optic nerve, and
reduced RGC density in the retina, especially in the
nasal quadrant. Systemic treatment with BMD signifi-
cantly improved axonal transport and survival and either
prevented or decreased loss of RGC density across ret-
inal quadrants. As transport deficits to and from RGC
targets are relevant to the progression of glaucoma, the
ability of BMD to preserve optic nerve axons and axonal
transport suggest its neuroprotective effects are perti-
nent not only at the cell body, but throughout the entire
retinal projection as well.
Methods
IOP elevation and brimonidine delivery
Unilateral IOP elevation in male Sprague-Dawley rats
(weight range, 350 - 400 g) was achieved by laser photo-
coagulation of episcleral and limbal veins as described
previously [11]. Rats were anesthetized with a mixture of
ketamine (50 mg/kg), acepromazine (1 mg/kg), and xyla-
zine (25 mg/kg) and two laser treatments were performed
1 week apart in order to achieve persistent IOP elevation.
IOP was measured with a tonometer (TonoLab; Colonial
Medical Supply, Franconia, NH). BMD (1 mg/kg/day) or
vehicle phosphate-buffered saline (PBS) was administered
systemically and continuously using an osmotic pump
(Alzet; Durect, Cupertino, CA) inserted subcutaneously
on the back of 16 animals per group. This concentration
and mode of delivery was based on earlier results com-
paring 0.5 mg/kg/day vs. 1 mg/kg/day for efficacy in pro-
tecting RGC cell bodies during OHT [11]. Treatment
began at the time of initial IOP elevation and continued
for 8 weeks. Age-matched naïve control rats (n = 16)
were also included for comparison.
Cholera toxin b injection and tissue preparation
Forty-eight hours prior to sacrifice, rats were anesthe-
tized with a mixture of ketamine (50 mg/kg) and xyla-
zine (25 mg/kg) and eyes anesthetized locally using
topical application of oxybuprocaine chlorhydrate [65].
The hypertensive eye received an intravitreal injection
(6 μl) of 0.5 mg Cholera toxin subunit b (CTB) conju-
gated to Alexa Fluor 594 (Molecular Probes, CA) while
the control eye received a similar injection of CTB con-
jugated to Alexa Fluor 488 (Molecular Probes, CA) fol-
lowing earlier studies [21]. After the 48 hour period,
animals were deeply anesthetized with a lethal intraperi-
toneal injection of sodium pentobarbital (150 mg/kg)
and perfused intracardially with warm (37°C) hepari-
nized saline followed by 300 ml of Zamboni’s fixative at
4°C. Brains were cryoprotected overnight in 30%
sucrose/PBS and 50 μm coronal sections were taken
through the midbrain and mounted on gelatin-coated
slides. Retinas were dissected from the eye and vitreous
removed after treatment with collagenase (400 units/ml)
at 37°C for 15 minutes. Sections of optic nerve 2-3 mm
proximal to the globe were isolated, post-fixed and pre-
pared for embedding and semi-thin sectioning as pre-
viously described [66,67].
Retinal ganglion cell number and CTB uptake
RGCs were immuno-labelled using antibodies against
phosphorylated neurofilament-heavy (SMI31, Sternberger
Monoclonal Incorporated, Baltimore, MD) following our
published protocol [21]. Confocal images (0.101 mm
2)
were captured on an Olympus FV-1000 inverted confocal
microscope along the midline of each retinal quadrant at
1 to 4 mm from the optic disc. The number of SMI31-
positive and CTB-positive RGCs per image were counted
and RGC density calculated as cells per mm
2.
Axon quantification
A 2- to 3-mm section of optic nerve proximal to the
globe was isolated, post-fixed for 1 hour in 4% para-
formaldehyde, and prepared for embedding and sem-
ithin sectioning [66]. Sections were stained with
para-phenylenediamine (PPD) and then photographed
using 100× oil-immersion and differential interference
contrast optics. Photomicrographs of each optic nerve
section were collected as a montage using an Olympus
Provis AX70 microscope with motorized X-Y-Z stage
and a digital CCD video camera. Each montage was con-
trast and edge-enhanced using the ImagePro software
package (Media Cybernetics, CA). An additional routine
was used to identify and count each axon in the montage
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Page 10 of 13for which a myelin sheath could be identified. We used
this information to calculate the mean local axon density
for each section of nerve. This was multiplied by the
cross-sectional area of the nerve section to obtain an esti-
mate of the total number of axons as described [66].
Measurement of anterograde transport
Alternate sections of the brain containing superior collicu-
lus were photographed using a Spot-RT camera on an
Olympus AX-70 upright microscope and intensity of label
was quantified using ImagePro (Media Cybernetics,
Bethesda, MD) as described previously [21]. After normal-
izing with respect to background, intensity was recorded
based on mediolateral location in the section. Intensity cal-
culations from alternate sections were then combined to
form a colorimetric representation of CTB signal across
the retinotopic collicular map. For each colliculus, we
determined the fraction of intact retinotopic map, defined
as the percent area with CTB signal ≥70% maximum.
Statistical analysis
Unless otherwise indicated, all data are presented as the
mean ± the standard error of the mean (SEM). SigmaPlot
for Windows version 11.0 (Systat Software, Inc,; Chicago,
IL) was used to calculate p values in comparing data using
either ANOVA or t tests for data meeting criteria for nor-
malcy or using non-parametric rank statistics for data
failing normalcy.
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